You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,730,879

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,730,879

Title:	Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e
Abstract:	Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e, compositions thereof, methods for their preparation, and methods for their use are disclosed.
Inventor(s):	Carra; Ernest (Foster City, CA), Gerber; Michael (Oakland, CA), Shi; Bing (Redwood City, CA), Sujino; Keiko (Edmonton, CA), Tran; Duong (Edmonton, CA), Wang; Fang (Foster City, CA), Evarts; Jerry B. (Seattle, WA)
Assignee:	Gilead Calistoga LLC (Foster City, CA)
Application Number:	15/257,053
Patent Claims:	1. A composition comprising polymorphic Form I and polymorphic Form II of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e, wherein: the polymorphic Form I has an X-ray powder diffraction pattern comprising characteristic peaks, plus or minus 0.2 degrees 2.theta., at 14.3 degrees 2.theta., 17.2 degrees 2.theta., 17.7 degrees 2.theta., 20.9 degrees 2.theta., 23.9 degrees 2.theta., and 24.9 degrees 2.theta.; and the polymorphic Form II has an X-ray powder diffraction pattern comprising characteristic peaks, plus or minus 0.2 degrees 2.theta., at 14.0 degrees 2.theta., 18.6 degrees 2.theta., and 24.3 degrees 2.theta.. 2. The composition of claim 1, wherein the weight ratio of polymorphic Form I to polymorphic Form II is between 90:1 and 99:1. 3. A composition comprising polymorphic Form I and polymorphic Form II of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-on- e, wherein the polymorphic Form I has an X-ray powder diffraction pattern substantially as shown in FIG. 1A, and wherein the polymorphic Form II has an X-ray powder diffraction pattern substantially as shown in FIG. 2A. 4. The composition of claim 3, wherein the weight ratio of polymorphic Form I to polymorphic Form II is between 90:1 and 99:1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.